DK3535263T3 - Substituerede pyrido[3,4-b]indoler til behandling af bruskforstyrrelser - Google Patents

Substituerede pyrido[3,4-b]indoler til behandling af bruskforstyrrelser Download PDF

Info

Publication number
DK3535263T3
DK3535263T3 DK17794307.3T DK17794307T DK3535263T3 DK 3535263 T3 DK3535263 T3 DK 3535263T3 DK 17794307 T DK17794307 T DK 17794307T DK 3535263 T3 DK3535263 T3 DK 3535263T3
Authority
DK
Denmark
Prior art keywords
indoles
disorders
customer
treatment
substituted pyrido
Prior art date
Application number
DK17794307.3T
Other languages
English (en)
Inventor
Dirk Gretzke
Olaf Ritzeler
Uwe Heinelt
Volkmar Wehner
Friedemann Schmidt
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK3535263T3 publication Critical patent/DK3535263T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK17794307.3T 2016-11-07 2017-11-02 Substituerede pyrido[3,4-b]indoler til behandling af bruskforstyrrelser DK3535263T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306452.0A EP3318563A1 (en) 2016-11-07 2016-11-07 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
PCT/EP2017/078026 WO2018083157A1 (en) 2016-11-07 2017-11-02 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Publications (1)

Publication Number Publication Date
DK3535263T3 true DK3535263T3 (da) 2020-12-21

Family

ID=57286428

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17794307.3T DK3535263T3 (da) 2016-11-07 2017-11-02 Substituerede pyrido[3,4-b]indoler til behandling af bruskforstyrrelser

Country Status (33)

Country Link
US (4) US11130755B2 (da)
EP (3) EP3318563A1 (da)
JP (1) JP7046063B2 (da)
KR (1) KR102490199B1 (da)
CN (1) CN110382496B (da)
AR (1) AR110136A1 (da)
AU (2) AU2017353381B2 (da)
CL (1) CL2019001251A1 (da)
CO (1) CO2019005090A2 (da)
CR (1) CR20190217A (da)
DK (1) DK3535263T3 (da)
DO (1) DOP2019000112A (da)
EA (1) EA038365B1 (da)
EC (1) ECSP19031458A (da)
ES (1) ES2837765T3 (da)
HR (1) HRP20201754T1 (da)
HU (1) HUE052187T2 (da)
IL (1) IL265982B (da)
LT (1) LT3535263T (da)
MA (1) MA45803B1 (da)
MX (1) MX383580B (da)
MY (1) MY189589A (da)
PE (1) PE20191032A1 (da)
PH (1) PH12019500997B1 (da)
PT (1) PT3535263T (da)
RS (1) RS61172B1 (da)
SG (1) SG11201903195YA (da)
SI (1) SI3535263T1 (da)
TN (1) TN2019000143A1 (da)
TW (1) TWI753966B (da)
UY (1) UY37473A (da)
WO (1) WO2018083157A1 (da)
ZA (1) ZA201902111B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
WO2019100062A1 (en) 2017-11-20 2019-05-23 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN111819193A (zh) 2018-01-05 2020-10-23 西奈山伊坎医学院 增加胰腺β细胞增殖的方法、治疗方法以及组合物
AU2019240065A1 (en) * 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
KR20220044721A (ko) * 2019-08-06 2022-04-11 도메인 테라퓨틱스 신경펩타이드 ff 수용체 길항제로서의 5-헤테로아릴-피리딘-2-아민 화합물
CN114763347B (zh) * 2021-01-15 2024-06-21 华东师范大学 一类用于诱导间充质干细胞向软骨分化的化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ194747A (en) * 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
ECSP951529A (es) 1995-09-05 1997-05-16 Compuestos farmaceuticos
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
US9248124B2 (en) 2001-11-07 2016-02-02 Millennium Pharmaceuticals, Inc. Use of inhibitors of IκB kinase for the treatment of cancer
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
JP4626613B2 (ja) * 2004-08-04 2011-02-09 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子
KR101419961B1 (ko) 2006-08-25 2014-07-30 아레스 트레이딩 에스.에이. Ｆｇｆ-18 로 연골 질환의 치료
WO2008132454A1 (en) 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
FR2916380B1 (fr) * 2007-05-21 2009-07-31 Saint Gobain Procede et dispositif de surmoulage d'un element vitre par une portion de joint comportant un insert, vitrage et insert notamment pour ce procede.
WO2010038153A1 (en) 2008-10-01 2010-04-08 The University Of British Columbia Use of sox transcription factor acti\ators for stimulating chondrogenesis
US9962368B2 (en) * 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2455378A1 (en) * 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
JP5854492B2 (ja) 2011-02-24 2016-02-09 国立大学法人 岡山大学 軟骨細胞分化誘導促進剤
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
JP2015107945A (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Also Published As

Publication number Publication date
CL2019001251A1 (es) 2019-10-04
CO2019005090A2 (es) 2019-07-31
AU2017353381B2 (en) 2021-05-27
KR20190072654A (ko) 2019-06-25
MA45803A1 (fr) 2020-05-29
WO2018083157A1 (en) 2018-05-11
CR20190217A (es) 2019-08-06
SI3535263T1 (sl) 2020-11-30
ZA201902111B (en) 2020-10-28
PH12019500997A1 (en) 2019-08-05
MX2019005308A (es) 2019-08-05
US11130755B2 (en) 2021-09-28
PH12019500997B1 (en) 2023-08-09
UY37473A (es) 2018-06-29
EP3535263B1 (en) 2020-09-30
IL265982A (en) 2019-06-30
ES2837765T3 (es) 2021-07-01
KR102490199B1 (ko) 2023-01-20
MX383580B (es) 2025-03-14
EP3792262B1 (en) 2026-04-15
EA038365B1 (ru) 2021-08-16
US20220041596A1 (en) 2022-02-10
AR110136A1 (es) 2019-02-27
SG11201903195YA (en) 2019-05-30
EA201991144A1 (ru) 2019-10-31
PE20191032A1 (es) 2019-08-05
EP3792262A1 (en) 2021-03-17
EP3535263A1 (en) 2019-09-11
MY189589A (en) 2022-02-18
MA45803B1 (fr) 2020-10-28
AU2021221468A1 (en) 2021-09-16
CN110382496A (zh) 2019-10-25
ECSP19031458A (es) 2019-05-31
JP2019537587A (ja) 2019-12-26
TW201831475A (zh) 2018-09-01
RS61172B1 (sr) 2021-01-29
HUE052187T2 (hu) 2021-04-28
US20250333412A1 (en) 2025-10-30
CN110382496B (zh) 2022-08-09
US20200095242A1 (en) 2020-03-26
US12275733B2 (en) 2025-04-15
US11827633B2 (en) 2023-11-28
TWI753966B (zh) 2022-02-01
US20240182469A1 (en) 2024-06-06
IL265982B (en) 2021-05-31
LT3535263T (lt) 2020-12-28
AU2017353381A1 (en) 2019-05-30
AU2021221468B2 (en) 2023-10-26
EP3318563A1 (en) 2018-05-09
DOP2019000112A (es) 2019-07-31
NZ753239A (en) 2024-07-26
PT3535263T (pt) 2020-12-18
CA3042332A1 (en) 2018-05-11
TN2019000143A1 (en) 2020-10-05
BR112019007901A2 (pt) 2019-07-02
JP7046063B2 (ja) 2022-04-01
HRP20201754T1 (hr) 2020-12-25

Similar Documents

Publication Publication Date Title
IL285151A (en) Methods of treating fgf21-associated disorders
DK3355884T3 (da) Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
HRP20210518T1 (hr) Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
EP3452481A4 (en) IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
DK3261640T3 (da) 5ht-agonister til behandling af epilepsilidelser
DK3139925T3 (da) Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
DK3380471T3 (da) Tetrahydro-8h-pyrido[1,2-a]pyrazin-8-oner som comt-inhibitorer til behandlingen af neurodegenerative lidelser
HUE052187T2 (hu) Helyettesített pirido[3,4-b]indolok porcrendellenességek kezelésére
LT3536324T (lt) 4-okso-3,4-dihidro-1,2,3-benzotriazinai, kaip gpr139 moduliatoriai
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3242888T3 (da) Opløselige fgfr3-atrapper til behandling af skeletvækstforstyrrelser
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
DK3506956T3 (da) Lægemiddel, særlig til behandling af fistler
DK3397621T3 (da) Fremgangsmåde til fremstilling af 1,1,3-trioxo-1,2-benzothiazol-6-carboxamid
DK3345581T3 (da) Elektrisk understøttet kørestol samt fremgangsmåde til styring af den elektrisk understøttede kørestol
DK3448382T3 (da) Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
IL244619A0 (en) Pyrido[3-b,4]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
DK3423440T3 (da) 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-on-derivat til behandlingen af hjernetumorer
DK3397620T3 (da) Fremgangsmåde til fremstilling af 1,1,3-Trioxo-1,2-benzothiazol-6-carboxamid
DK3356329T3 (da) Fremgangsmåde til fremstilling af 1-(4-methansulfonyl-2-trifluormethylbenzyl)-2-methyl-1H-pyrrolo[2,3-B]pyridin-3-yleddikesyre
LT3356337T (lt) Tricikliniai dibenzotiazepino tipo junginiai, skirti cdkl5 sutrikimų gydyme